Cargando…

Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

The authors wish to make the following corrections to their article: Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232657/ https://www.ncbi.nlm.nih.gov/pubmed/34234832 http://dx.doi.org/10.7573/dic.2021-5-2

Ejemplares similares

The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
por: Efimov, Sergey V, et al.
Publicado: (2021)

Azoximer Bromide: Mystery, Serendipity, and Promise
por: Grivtsova, Lyudmila Yuryevna, et al.
Publicado: (2021)

Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.
por: Kompier, Ronald, et al.
Publicado: (2022)

Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial – CORRIGENDUM
por: Dai, Minhan, et al.
Publicado: (2021)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Publicado: (2013)

Corrigendum to: The DNA intercalators ethidium bromide and propidium iodide also bind to core histones
Publicado: (2022)

Corrigendum to “Long-Term Effects of Goshajinkigan in Prevention of Diabetic Complications: A Randomized Open-Labeled Clinical Trial”
por: Watanabe, K., et al.
Publicado: (2016)

Corrigendum to: Nurses’ knowledge on phlebotomy in tertiary hospitals in China: a cross-sectional multicentric survey
por: Cai, Qian, et al.
Publicado: (2018)

Corrigendum to “Effects of Shenfu Injection in the Treatment of Septic Shock Patients: A Multicenter, Controlled, Randomized, Open-Label Trial”
por: Li, Yi, et al.
Publicado: (2016)

The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study [Corrigendum]
Publicado: (2022)

Evaluating intervention strategies in controlling coronavirus disease 2019 (COVID-19) spread in care homes: An agent-based model – CORRIGENDUM
por: Nguyen, Le Khanh Ngan, et al.
Publicado: (2022)

Corrigendum to “Risk Factors for Fracture in Diabetes: The Canadian Multicentre Osteoporosis Study”
por: Fraser, Lisa-Ann, et al.
Publicado: (2017)

Polyoxidonium(®) Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer
por: Alexia, Catherine, et al.
Publicado: (2019)

Corrigendum to ‘External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019’
por: Hassan, Shermarke, et al.
Publicado: (2022)

A Prospective, Open-Label Study to Evaluate the Impact of VYC-12L Injection on Skin Quality Attributes in Healthy Volunteers [Corrigendum]
Publicado: (2022)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
Publicado: (2015)

Corrigendum to: Rice Galaxy: an open resource for plant science
por: Juanillas, Venice, et al.
Publicado: (2019)

One health surveillance strategy for coronaviruses in Italian wildlife – CORRIGENDUM
por: Leopardi, Stefania, et al.
Publicado: (2023)

Corrigendum to “Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring”
por: Macchia, Iole, et al.
Publicado: (2020)

Corrigendum to aPDT for oral decontamination of hospitalized patients with COVID 19()
por: Morimoto, Susana, et al.
Publicado: (2022)

Corrigendum to: Temporal Changes in the Risk of Superspreading Events of Coronavirus Disease 2019
por: Lim, Jun-Sik, et al.
Publicado: (2021)

Plagues, pandemics and epidemics in Irish history prior to Covid-19 (coronavirus): What can we learn? - Corrigendum
por: Kelly, Brendan D.
Publicado: (2020)

Evaluation of prevalence and risk factors for bloodstream infection in severe coronavirus disease 2019 (COVID-19) patients – CORRIGENDUM
por: Erbay, Kubra, et al.
Publicado: (2022)

Corrigendum: Lymphangiographic Interventions to Manage Postoperative Chylothorax
por: Jeong, Hyuncheol, et al.
Publicado: (2020)

Corrigendum to: Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry
por: Ohashi, Yasuo, et al.
Publicado: (2020)

Obstructive sleep apnea affects the clinical outcomes of patients undergoing percutaneous coronary intervention [Corrigendum]
Publicado: (2016)

BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase [Corrigendum]
Publicado: (2015)

Corrigendum to “Epigenetic and Neural Circuitry Landscape of Psychotherapeutic Interventions”
por: Miller, Christopher W. T.
Publicado: (2017)

Corrigendum to: Family-joining: A fast distance-based method for constructing generally labeled trees
por: Kalaghatgi, Prabhav, et al.
Publicado: (2020)

Corrigendum to “Prognostic Factors for COVID-19 Hospitalized Patients with Preexisting Type 2 Diabetes”
por: Fu, Yuanyuan, et al.
Publicado: (2022)

Corrigendum to “Open Periprosthetic Knee Fracture: A Case Report and Review of the Literature”
Publicado: (2020)

Corrigendum to “VISTO: An open-source device to measure exposure time in psychological experiments”
por: De Cesarei, Andrea, et al.
Publicado: (2021)

Corrigendum to “The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China” [J. Autoimmun. 109C (2020) 102434]
por: Yang, Yongshi, et al.
Publicado: (2020)

Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
por: Pandit, Anuja, et al.
Publicado: (2021)

CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing
por: Suwa, Michihiro, et al.
Publicado: (2023)

Improving the Efficacy of Antimicrobials against Biofilm-Embedded Bacteria Using Bovine Hyaluronidase Azoximer (Longidaza(®))
por: Trizna, Elena, et al.
Publicado: (2021)

Corrigendum to “Simulation of the Final Size of the Evolution Curve of Coronavirus Epidemic in Morocco using the SIR Model”
por: Ifguis, Ousama, et al.
Publicado: (2022)

Corrigendum: Gestational age and birth weight variations in young children with language impairment at an early communication intervention clinic
por: Fouché, Lauren C., et al.
Publicado: (2019)

Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: a multicentre, open-label, randomised study
por: Kamei, Tadashi, et al.
Publicado: (2019)

Microbial Profile and Clinical Outcomes of Fungal Keratitis at a Single-Center Tertiary Care Hospital [Corrigendum]
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_se564t0t64if3ls9cebsttk67l